Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Deyn, P. P.
Right arrow Articles by Lawlor, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Deyn, P. P.
Right arrow Articles by Lawlor, B. A.
Neurology 1999;53:946
© 1999 American Academy of Neurology


Articles

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia

P. P. De Deyn, MD, K. Rabheru, MD, A. Rasmussen, MD, J. P. Bocksberger, MD, P. L. J. Dautzenberg, MD, S. Eriksson, MD and B. A. Lawlor, MD

From the Department of Neurology, General Hospital Middelheim and Laboratory of Neurochemistry and Behavior (Dr. De Deyn), Born-Bunge Foundation, University of Antwerp, Belgium; London Psychiatric Hospital (Dr. Rabheru), London, Ontario, Canada; Psychatric Research Clinic (Dr. Rasmussen), Frederiksberg Hospital, Frederiksberg, Denmark; University Hospital Geneva (Dr. Bocksberger), Geneva, Switzerland; Bosch Medicentrum, ’s Hertogenbosch, The Netherlands (Dr. Dautzenberg); Department of Geriatric Medicine (Dr. Eriksson), University of Umeå, Umeå, Sweden; and Department of Psychiatry (Dr. Lawlor), Jonathan Swift Clinic, St. James’s Hospital, Dublin, Ireland.

Address correspondence and reprint requests to Professor P.P. De Deyn, Department of Neurology, General Hospital Middelheim and Laboratory of Neurochemistry and Behavior, Born-Bunge Foundation, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk-Antwerp, Belgium; e-mail: ppdedeyn{at}uia.ua.ac.be

OBJECTIVE: To compare effects of risperidone with placebo (efficacy and tolerability) and haloperidol (tolerability) for treating demented patients with aggression and other behavioral symptoms.

METHODS: A 13-week double-blind study involving 344 patients with dementia randomly assigned to receive placebo or flexible doses (0.5 to 4 mg/d) of risperidone or haloperidol. Behavioral symptoms were assessed by the Behavior Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD), the Cohen-Mansfield Agitation Inventory (CMAI), and the Clinical Global Impression (CGI) scale. Tolerability assessments included the Extrapyramidal Symptom Rating Scale, sedation levels, Functional Assessment Staging, Mini-Mental State Examination, and incidence of adverse events.

RESULTS: The mean dose at endpoint was 1.1 mg/d of risperidone and 1.2 mg/d of haloperidol. Although not significant, a higher percentage of patients receiving risperidone than those receiving placebo showed clinical improvement (>=30% reduction from baseline to endpoint in BEHAVE-AD total score) at endpoint and week 12. Reductions in the BEHAVE-AD total score were significantly greater with risperidone than with placebo at week 12. In a further analysis of aggression, the most dominant symptom in these patients, BEHAVE-AD and CMAI aggression cluster scores were significantly reduced compared with placebo at endpoint and week 12. CGI scores were also significantly reduced at endpoint and week 12. Severity of extrapyramidal symptoms with risperidone did not differ significantly from that of placebo and was less than that of haloperidol. A post hoc analysis showed significantly greater reductions in the BEHAVE-AD aggressiveness score with risperidone than haloperidol at week 12.

CONCLUSION: Low-dose risperidone (mean 1.1 mg/d) was well tolerated and associated with reductions in the severity and frequency of behavioral symptoms, particularly aggression, in elderly patients with dementia.

Key words: Risperidone—Aggression—Behavioral symptoms—Dementia—Extrapyramidal symptoms.




This article has been cited by other articles:


Home page
AJGPHome page
J. E. Streim, A. P. Porsteinsson, C. D. Breder, R. Swanink, R. Marcus, R. McQuade, and W. H. Carson
A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease
Am J Geriatr Psychiatry, July 1, 2008; 16(7): 537 - 550.
[Abstract] [Full Text] [PDF]


Home page
DTBHome page
How safe are antipsychotics in dementia?
DTB, November 1, 2007; 45(11): 81 - 85.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
J. E. Mintzer, L. E. Tune, C. D. Breder, R. Swanink, R. N. Marcus, R. D. McQuade, and A. Forbes
Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses
Am J Geriatr Psychiatry, November 1, 2007; 15(11): 918 - 931.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
B. G. Pollock, B. H. Mulsant, J. Rosen, S. Mazumdar, R. E. Blakesley, P. R. Houck, and K. A. Huber
A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia
Am J Geriatr Psychiatry, November 1, 2007; 15(11): 942 - 952.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
H. C. Kales, M. Valenstein, H. M. Kim, J. F. McCarthy, D. Ganoczy, F. Cunningham, and F. C. Blow
Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications
Am J Psychiatry, October 1, 2007; 164(10): 1568 - 1576.
[Abstract] [Full Text] [PDF]


Home page
Qual Health ResHome page
P. C. Kontos and G. Naglie
Expressions of Personhood in Alzheimer's Disease: An Evaluation of Research-Based Theatre as a Pedagogical Tool
Qual Health Res, July 1, 2007; 17(6): 799 - 811.
[Abstract] [PDF]


Home page
AJGPHome page
S. I. Sharp, C. G. Ballard, C. P. L.-H. Chen, and P. T. Francis
Aggressive Behavior and Neuroleptic Medication Are Associated With Increased Number of Alpha1-Adrenoceptors in Patients With Alzheimer Disease
Am J Geriatr Psychiatry, May 1, 2007; 15(5): 435 - 437.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. Kurlan, J. Cummings, R. Raman, L. Thal, and For the Alzheimer's Disease Cooperative Study Grou
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism
Neurology, April 24, 2007; 68(17): 1356 - 1363.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
M. L. Onor, M. Saina, and E. Aguglia
Efficacy and Tolerability of Quetiapine in the Treatment of Behavioral and Psychological Symptoms of Dementia
American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 448 - 453.
[Abstract] [PDF]


Home page
AJGPHome page
P. N. Tariot, L. Schneider, I. R. Katz, J. E. Mintzer, J. Street, M. Copenhaver, and C. Williams-Hughes
Quetiapine Treatment of Psychosis Associated With Dementia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Am J Geriatr Psychiatry, September 1, 2006; 14(9): 767 - 776.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. Leonard, M. E. Tinetti, H. G. Allore, and M. A. Drickamer
Potentially modifiable resident characteristics that are associated with physical or verbal aggression among nursing home residents with dementia.
Arch Intern Med, June 26, 2006; 166(12): 1295 - 1300.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
G. J Andrews
Managing challenging behaviour in dementia.
BMJ, April 1, 2006; 332(7544): 741 - 741.
[Full Text] [PDF]


Home page
BMJHome page
J. Fossey, C. Ballard, E. Juszczak, I. James, N. Alder, R. Jacoby, and R. Howard
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial
BMJ, April 1, 2006; 332(7544): 756 - 761.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
L. S. Schneider, K. Dagerman, and P. S. Insel
Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials
Am J Geriatr Psychiatry, March 1, 2006; 14(3): 191 - 210.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
J. Mintzer, A. Greenspan, I. Caers, I. Van Hove, S. Kushner, M. Weiner, G. Gharabawi, and L. S. Schneider
Risperidone in the Treatment of Psychosis of Alzheimer Disease: Results From a Prospective Clinical Trial
Am J Geriatr Psychiatry, March 1, 2006; 14(3): 280 - 291.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
P. Aupperle
Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics
American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 101 - 108.
[Abstract] [PDF]


Home page
AJGPHome page
J. Rabinowitz, M. Davidson, P. P. De Deyn, I. Katz, H. Brodaty, and J. Cohen-Mansfield
Factor Analysis of the Cohen-Mansfield Agitation Inventory in Three Large Samples of Nursing Home Patients With Dementia and Behavioral Disturbance
Am J Geriatr Psychiatry, November 1, 2005; 13(11): 991 - 998.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
L. S. Schneider, K. S. Dagerman, and P. Insel
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials
JAMA, October 19, 2005; 294(15): 1934 - 1943.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
H. H. Feldman and M. Woodward
The staging and assessment of moderate to severe Alzheimer disease
Neurology, September 27, 2005; 65(6_suppl_3): S10 - S17.
[Abstract] [Full Text]


Home page
NeurologyHome page
J. L. Cummings
Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease
Neurology, September 27, 2005; 65(6_suppl_3): S18 - S24.
[Full Text]


Home page
Arch Intern MedHome page
P. A. Rochon, T. A. Stukel, K. Sykora, S. Gill, S. Garfinkel, G. M. Anderson, S.-L. T. Normand, M. Mamdani, P. E. Lee, P. Li, et al.
Atypical Antipsychotics and Parkinsonism
Arch Intern Med, September 12, 2005; 165(16): 1882 - 1888.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
W. G. Deberdt, M. W. Dysken, S. A. Rappaport, P. D. Feldman, C. A. Young, D. P. Hay, D. L. Lehman, M. Dossenbach, E. K. Degenhardt, and A. Breier
Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia
Am J Geriatr Psychiatry, August 1, 2005; 13(8): 722 - 730.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
S. Karim and E. J. Byrne
Treatment of psychosis in elderly people
Advan. Psychiatr. Treat., July 1, 2005; 11(4): 286 - 296.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. A. Briesacher, M. R. Limcangco, L. Simoni-Wastila, J. A. Doshi, S. R. Levens, D. G. Shea, and B. Stuart
The Quality of Antipsychotic Drug Prescribing in Nursing Homes
Arch Intern Med, June 13, 2005; 165(11): 1280 - 1285.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. M. Sink, K. F. Holden, and K. Yaffe
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
JAMA, February 2, 2005; 293(5): 596 - 608.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
I. R. Katz, M. Rupnow, C. Kozma, and L. Schneider
Risperidone and Falls in Ambulatory Nursing Home Residents With Dementia and Psychosis or Agitation: Secondary Analysis of a Double-Blind, Placebo-Controlled Trial
Am J Geriatr Psychiatry, October 1, 2004; 12(5): 499 - 508.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
G.-H. Suh, H. G. Son, Y.-S. Ju, K. H. Jcho, B. K. Yeon, Y. M. Shin, B. S. Kee, and S.-K. Choi
A Randomized, Double-Blind, Crossover Comparison of Risperidone and Haloperidol in Korean Dementia Patients With Behavioral Disturbances
Am J Geriatr Psychiatry, October 1, 2004; 12(5): 509 - 516.
[Abstract] [Full Text] [PDF]


Home page
GerontologistHome page
B. D. Lebowitz
Clinical Trials in Late Life: New Science in Old Paradigms
Gerontologist, August 1, 2004; 44(4): 452 - 458.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
F. Assal, M. Alarcon, E. C. Solomon, D. Masterman, D. H. Geschwind, and J. L. Cummings
Association of the Serotonin Transporter and Receptor Gene Polymorphisms in Neuropsychiatric Symptoms in Alzheimer Disease
Arch Neurol, August 1, 2004; 61(8): 1249 - 1253.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Holmes, D. Wilkinson, C. Dean, S. Vethanayagam, S. Olivieri, A. Langley, N. D. Pandita-Gunawardena, F. Hogg, C. Clare, and J. Damms
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Neurology, July 27, 2004; 63(2): 214 - 219.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
P. E Lee, S. S Gill, M. Freedman, S. E Bronskill, M. P Hillmer, and P. A Rochon
Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review
BMJ, July 10, 2004; 329(7457): 75.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. L. Cummings
Alzheimer's Disease
N. Engl. J. Med., July 1, 2004; 351(1): 56 - 67.
[Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
K. Meguro, M. Meguro, Y. Tanaka, K. Akanuma, K. Yamaguchi, and M. Itoh
Risperidone is Effective for Wandering and Disturbed Sleep/Wake Patterns in Alzheimer's Disease
J Geriatr Psychiatry Neurol, June 1, 2004; 17(2): 61 - 67.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
N. Herrmann, M. Mamdani, and K. L. Lanctot
Atypical Antipsychotics and Risk of Cerebrovascular Accidents
Am J Psychiatry, June 1, 2004; 161(6): 1113 - 1115.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
J. A. Cheong
An Evidence-Based Approach to the Management of Agitation in the Geriatric Patient
Focus, April 1, 2004; 2(2): 197 - 205.
[Full Text] [PDF]


Home page
FocusHome page
O. A. Ajilore and A. Kumar
Delirium and Dementia
Focus, April 1, 2004; 2(2): 210 - 220.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Focus, April 1, 2004; 2(2): 268 - 281.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
R. L. Maher Jr
The Pharmacological Approach of Behavioral Disturbances in Dementia
Journal of Pharmacy Practice, April 1, 2004; 17(2): 129 - 132.
[Abstract] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
R. Moretti, P. Torre, R. M. Antonello, T. Cattaruzza, G. Cazzato, and A. Bava
Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study
American Journal of Alzheimer's Disease and Other Dementias, March 1, 2004; 19(2): 81 - 88.
[Abstract] [PDF]


Home page
NEJMHome page
A. M. Clarfield, F. J. Ruiz-Ruiz, R. S. Hausner, R. Mahmoud, A. Greenspan, C. O'Dwyer, D. O'Shea, and C. H. Kawas
Early Alzheimer's Disease
N. Engl. J. Med., January 1, 2004; 350(1): 80 - 82.
[Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
J. Mintzer and S. D. Targum
Psychosis in Elderly Patients: Classification and Pharmacotherapy
J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 199 - 206.
[Abstract] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
N. Hoeh, L. Gyulai, D. Weintraub, and J. Streim
Pharmacologic Management of Psychosis in the Elderly: A Critical Review
J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 213 - 218.
[Abstract] [PDF]


Home page
NeurologyHome page
D. L. Murman, S. B. Kuo, M. C. Powell, and C. C. Colenda
The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies
Neurology, October 14, 2003; 61(7): 944 - 949.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
M. M. Bassiony and C. G. Lyketsos
Delusions and Hallucinations in Alzheimer's Disease: Review of the Brain Decade
Psychosomatics, October 1, 2003; 44(5): 388 - 401.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. H. Kawas
Early Alzheimer's Disease
N. Engl. J. Med., September 11, 2003; 349(11): 1056 - 1063.
[Full Text] [PDF]


Home page
AJGPHome page
A. P. Porsteinsson, P. N. Tariot, L. J. Jakimovich, N. Kowalski, C. Holt, R. Erb, and C. Cox
Valproate Therapy for Agitation in Dementia: Open-Label Extension of a Double-Blind Trial
Am J Geriatr Psychiatry, August 1, 2003; 11(4): 434 - 440.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
G. H. Pelton, D. P. Devanand, K. Bell, K. Marder, K. Marston, X. Liu, and T. B. Cooper
Usefulness of Plasma Haloperidol Levels for Monitoring Clinical Efficacy and Side Effects in Alzheimer Patients With Psychosis and Behavioral Dyscontrol
Am J Geriatr Psychiatry, April 1, 2003; 11(2): 186 - 193.
[Abstract] [Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
O. L. Lopez, J. T. Becker, R. A. Sweet, W. Klunk, D. I. Kaufer, J. Saxton, and S. T. DeKosky
Patterns of Change in the Treatment of Psychiatric Symptoms in Patients With Probable Alzheimer's Disease From 1983 to 2000
J Neuropsychiatry Clin Neurosci, February 1, 2003; 15(1): 67 - 73.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
Q. Zhao, C. Xie, L. Pesco-Koplowitz, X. Jia, and J.-L. Parier
Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil
J. Clin. Pharmacol., February 1, 2003; 43(2): 180 - 186.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D.L. Murman, Q. Chen, M.C. Powell, S.B. Kuo, C.J. Bradley, and C.C. Colenda
The incremental direct costs associated with behavioral symptoms in AD
Neurology, December 10, 2002; 59(11): 1721 - 1729.
[Abstract] [Full Text] [PDF]


Home page
Br. J. PsychiatryHome page
B. LAWLOR
Managing behavioural and psychological symptoms in dementia
The British Journal of Psychiatry, December 1, 2002; 181(6): 463 - 465.
[Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
J. M. Ryan, S. W. Kidder, L. A. Daiello, and P. N. Tariot
Mental Health Services in Nursing Homes: Psychopharmacologic Interventions in Nursing Homes: What Do We Know and Where Should We Go?
Psychiatr Serv, November 1, 2002; 53(11): 1407 - 1413.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Psychiatr Serv, November 1, 2002; 53(11): 1419 - 1431.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study
JAMA, September 25, 2002; 288(12): 1475 - 1483.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
W. Breitbart, A. Tremblay, and C. Gibson
An Open Trial of Olanzapine for the Treatment of Delirium in Hospitalized Cancer Patients
Psychosomatics, June 1, 2002; 43(3): 175 - 182.
[Abstract] [Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
R. A. Maxwell, R. A. Sweet, B. H. Mulsant, J. Rosen, M. A. Kirshner, K. B. Kastango, and B. G. Pollock
Risperidone and 9-Hydroxyrisperidone Concentrations Are Not Dependent on Age or Creatinine Clearance among Elderly Subjects
J Geriatr Psychiatry Neurol, June 1, 2002; 15(2): 77 - 81.
[Abstract] [PDF]


Home page
NeurologyHome page
N. Scarmeas, J. Brandt, M. Albert, D. P. Devanand, K. Marder, K. Bell, A. Ciappa, B. Tycko, and Y. Stern
Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease
Neurology, April 23, 2002; 58(8): 1182 - 1188.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
W. P. Bouman and G. Pinner
Use of atypical antipsychotic drugs in old age psychiatry
Advan. Psychiatr. Treat., January 1, 2002; 8(1): 49 - 58.
[Full Text] [PDF]


Home page
J Am Psychiatr Nurses AssocHome page
M. A. Boyd
Behavioral Disturbances Associated with Dementia: Nursing Implications
Journal of the American Psychiatric Nurses Association, December 1, 2001; 7(6): S14 - S22.
[Abstract] [PDF]